Please note
This trial is no longer recruiting patients. We hope to add results when they are available.
Blood cancers, Chronic leukaemia, Chronic myeloid leukaemia (CML), Leukaemia
Closed
Phase 3
This study is comparing a new drug called asciminib with bosutinib for chronic myeloid leukaemia (CML).
It is for people who have had already treatment with 2 or more drugs such as imatinib, dasatinib or nilotinib.
Recruitment start: 26 March 2018
Recruitment end: 29 October 2019
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Prof. Adam Mead
Novartis
Last reviewed: 4 February 2020
CRUK internal database number: 15300
About Cancer generously supported by Dangoor Education since 2010. Learn more about Dangoor Education
What to ask your doctor about clinical trials.
Meet and chat to other cancer people affected by cancer.
Questions about cancer? Call freephone 0808 800 40 40 from 9 to 5 - Monday to Friday. Alternatively, you can email us.
